Ultraviolet A Combined with Narrow-Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow-Band Ultraviolet B: A Retrospective Cohort Study

Background. Psoralen plus ultraviolet A (PUVA) is the preferred phototherapeutic modality for early-stage folliculotropic mycosis fungoides (FMF), and non-FMF refractory to narrow-band B (NBUVB). However, PUVA has a problematic safety profile. Literature on treatment with combination of UVA NBUVB MF sparse. Objective. To evaluate effectiveness combined MF, specifically FMF NBUVB-refractory non-FMF, in adult pediatric patients. Methods. retrospective analysis was conducted patients treated at our center, during 1/2008–8/2022. Results. The cohort included 51 patients: 35 adults 16 overall response rate (ORR) 39 early-FMF (25 14 children) 95%, complete (CR) 62%. No significant differences ORR/CR rates were noted between Of 12 (10 2 children), ORR 83% CR 50%. In 17 (8 9 non-FMF), prior therapy resulted partial response/stable disease; yet, + led (4 5 non-FMF). Side effects minimal. Conclusion. Combined good alternative or , NBUVB.